Torin 2 (Torin2)是一种可口服的mTOR选择性抑制剂，EC₅₀为0.25 nM，比对PI3K和其它蛋白激酶的选择性高800倍。Torin 2还能抑制抑制ATM/ATR/DNA-PK。Torin2比Torin1更易生产，药代动力学特性也有改善，在体内具有良好的利用率。

参考文献

1. Liu Q, et al. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 2011 Mar 10;54(5):1473-80.
2. Liu Q, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013 Apr 15;73(8):2574-86.
3. Tamburrino A, et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 2012 Jul 1;18(13):3532-40.
4. Wang X, et al. mTORC signaling in hematopoiesis. Int J Hematol. 2016 May;103(5):510-8.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃干燥保存，避免反复冻融。